MAS-825 by Novartis for Coronary Artery Disease (CAD) (Ischemic Heart Disease): Likelihood of Approval
MAS-825 is under clinical development by Novartis and currently in Phase II for Coronary Artery Disease (CAD) (Ischemic Heart Disease).
MAS-825 is under clinical development by Novartis and currently in Phase II for Coronary Artery Disease (CAD) (Ischemic Heart Disease).
What's Your Reaction?
